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Abstract The capacity to regenerate damaged tissue and
appendages is lost to some extent in higher vertebrates such
as mammals, which form a scar tissue at the expenses of
tissue reconstitution and functionality. Whereas this process
can protect from further damage and elicit fast healing, it
can lead to functional deterioration in organs such as the
heart. Based on the analyses performed in the last years,
stem cell therapies may not be sufficient to induce cardiac
regeneration and additional approaches are required to over-
come scar formation. Among these, the immune cells and
their humoral response have become a key parameter in
regenerative processes. In this review, we will describe the
recent findings on the possible therapeutical use of progenitor
and immune cells to rescue a damaged heart.
Keywords Cardiac progenitor cells . Macrophage
populations . Cardiac regeneration . Fibrosis . Inflammation
Introduction
Regeneration of organs and appendages in lower vertebrates
is a process that involves several molecular and cellular
mediators including bioelectrical signals, thrombin activa-
tion, immuno-modulation, wound epithelium formation and
stem cell activation. In mammals, tissues such as liver, skin
and endometrium can regenerate, presumably due to their
normally high turnover rate. Rare examples of mammalian
appendage regeneration include seasonal deer antler growth
[1]. These regenerative properties account for cell cycle re-
entry (liver), stem cell differentiation (skin) and wound
epithelium formation (deer antler growth), resembling pro-
cesses observed in lower vertebrates.
An emerging concept is that the mammalian heart also
retains regenerative potential reminiscent of lower vertebrate
cardiac repair, but the cardiac regenerative response might be
insufficient to repair the extensive damage caused by myocar-
dial infarct (MI), the most common type of cardiac insult in
humans. Although resident cardiac stem cells have been
reported to replenish the injured myocardium [2], a complete
functional recovery after damage is not achieved.
A recent report suggests that the fully regenerative mech-
anisms in zebrafish hearts, which are mediated by cardiomyo-
cyte proliferation, are latent in mammalian heart. Indeed, a
murine model resembling zebrafish heart injury showed that
resection of the left ventricular apex in 1-day-old neonatal
mice induces cardiomyocyte proliferation and full heart re-
generation in 8 weeks [3]. Notably, the proliferative response
was lost in 7-day-old mice, coinciding with cardiomyocytes
binucleation and increased cardiac workload.
Cardiomyocyte turnover in adult humans is a rare event,
as measured by the level of 14C in proliferating cardiac cells
making use of the atmospheric increased of this isotope as
consequence of nuclear weapons’ testing during the Cold
War. The analysis showed that only 45 % of cardiomyocytes
would be predicted to be renewed over a normal human
lifespan [4]. Nonetheless, these studies leave open the for-
mal possibility that the processes of regeneration mediated
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by cardiomyocytes proliferation could be re-habilitated after
injury, by reversing the mechanisms that block cell-cycle re-
entry in a controlled therapeutic setting.
Two additional prerequisites must be satisfied for success-
ful regeneration of the cardiac ischaemic region. Coronary
arterioles and capillary structures must be formed in order to
bridge the dead tissue and establish communication with the
normally perfused vessels of the viable myocardium. Addi-
tionally, the new vascular supply has to permeate the myocyte
bed to preserve their survival, and favour their growth,
differentiation and contractile function.
In mammals, the presence of a circulating cell population
that could restore cardiac vasculature has gained credibility
from observations that CD34-positive cells from human
peripheral blood localize to areas of neovascularization
when injected into nude mice with hindlimb ischemia [5].
The dearth of information regarding the precise origin and
function of circulating endothelial progenitor cells (EPCs)
has prompted animal experiments in which stem cells iso-
lated from bone marrow [6–8] or peripheral blood [9] and
enriched for various surface markers were analysed for their
regenerative properties to restore cardiac function and form
new blood vessels. Despite these initial analyses, subse-
quent studies in animals with reconstituted genetically
marked bone marrow (LacZ, GFP) concluded that bone
marrow-derived cells were detectable only as perivascular
cells supporting the growth of new vessels but were not
integrated in the forming vessels [10, 11]. Thus, it appears
that the majority of endothelial-like cells in the peripheral
blood are monocytes that activate resident EPCs to form
vessels by releasing a plethora of pro-angiogenic factors.
Based on emerging evidence for immune engagement in
regeneration, here we propose novel ways in which combi-
natorial stem cell treatment and modulation of the immune
cells may have important therapeutic and pharmacological
implications for clinical treatment of heart disease.
Stem Cells for Cardiac Regeneration
Reminiscent of developmental programs, adult mammalian
heart seems to retain stem cell populations capable of multi-
potent differentiation. These cells have been variously de-
scribed as different populations by the expression of specific
cell surface markers (c-kit, Sca-1 and MDR-1).
In recent years, numerous studies have aimed to deter-
mine the efficiency of those stem cells to regenerate the
heart via cell therapy combined with tempering the hostile
environment of the infarct by administration of cell survival
and anti-inflammatory molecules. Important advances in the
control of stem cell fate have also moved the field of
regenerative medicine closer towards applicable therapies
for cardiac muscle regeneration. However, significant
obstacles must still be overcome, including the incomplete
cell differentiation of stem cells (with the associated danger
of tumour formation), the paucity of organ-specific stem cell
resources (specifically in adult/aged organs) and the immu-
nogenicity of the transplanted cells (graft rejection).
Cardiac Stem Cells
The earliest cardiovascular progenitors to be traced and
studied during embryogenesis express the transcription fac-
tor Islet 1 (Isl1) [12]. Isl1-null hearts failed to undergo
looping morphogenesis and appeared to have a common
atrium and a uni-ventricular chamber, whereas the right
ventricle and the outflow tract were absent [13]. These
observations suggest that Isl1 is expressed in cells of the
second heart field, which contribute to both the venous and
arterial poles of the heart [12]. Interestingly, Prall and co-
workers report that, in contrast to Isl1 mRNA, Isl1 protein is
expressed at E7.5 throughout the anterior intra-embryonic
coelomic walls and proximal head mesenchyme, regions
that encompass both first and second heart fields in mouse
[14]. Similarly, during neurula stages in Xenopus, Isl1 is co-
expressed with Nkx2-5 throughout the cardiac crescent,
which is the first heart field in amphibians [15]. These data
suggest that Isl1 might be a pan-cardiac progenitor marker,
but additional work is needed to clarify this issue.
Using conditional genetic marking techniques in themouse,
Laugwitz and co-authors performed Cre-recombinase-
triggered cell lineage tracing experiments to irreversibly mark
isl1-expressing cells as well as their differentiated progeny
during embryonic development [16]. Isl1-IRES-Cre mice were
crossed into the conditional Cre reporter strain R26R, in which
Cre-mediated removal of a stop sequence results in the ubiq-
uitous expression of the lacZ gene under the control of the
endogenous Rosa26 promoter [16]. The analysis showed that
Isl1+ progenitors make a remarkable contribution to the cells
of the conduction system, primarily to the sino-atrial node.
Additionally, galactosidase positive staining has been observed
throughout the proximal aorta, the trunk of the pulmonary
artery and the stems of the main left and right coronary
arteries [16]. The co-expression of lacZ with endothelial and
smooth muscle-specific markers, such as CD31 (Pecam1),
VE-cadherin (cadherin 5) and smooth muscle myosin heavy
chain (SM-MHC; also known as myosin heavy chain 11),
revealed that Isl1+ precursors can give rise to vascular
lineages [16].
In vitro, by tamoxifen inducible Cre-lox technology,
postnatal Isl1+ cell population and its progeny have been
selectively marked at a defined time and purified to relative
homogeneity [16]. The ability of these cells to self-renew on
a cardiac mesenchymal feeder layer and to be stimulated to
differentiate into fully mature functional cardiomyocytes
indicates that they represent native cardiac progenitors,
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remnants of the embryonic Isl1+ precursors [16]. Recently,
the presence of Isl1 cells in the adult murine heart has been
identified as clusters in the inter-atrial septum, scattered in
the wall of the great vessels, and as a delimited cluster
between the right atrium and the superior vena cava [17].
Notably, in this report the authors observed that Isl1+ cell
number and localization remained unchanged between 1 to
18 months of age [17]. Furthermore, these cells were not
present at the infarcted area 28 days after myocardial infarct
induction [17], suggesting that that Isl1-positive cells are not
a source of cardiac progenitors.
Recently, cardiac stem cells (CSCs) residing in the epi-
cardium have received considerable attention. This outer
layer of cells surrounding the myocardial tissue has been
shown to have an important role in regeneration of zebrafish
[18] and of the mammalian heart [19, 20]. These studies
reported that at least a subset of Sca-1+ cells originally
shown to reside in the murine heart are of epicardial origin
and can differentiate into all cardiac cell types, highlighting
the importance of the epicardium in mammalian cardiac
stem cell-mediated repair.
In the first study [20], activated adult progenitors were
shown to re-express a key embryonic epicardial gene, Wilm’s
tumour 1 (Wt1), after myocardial injury. Furthermore, these
cells are positive for Sca-1 and give rise to de novo cardio-
myocytes that structurally and functionally integrate with
resident muscle after treatment with thymosin β4 [20].
In the second report [19], a subpopulation expressing the
platelet-derived growth factor receptor alpha was found
amongst the cells positive for Wt1 and Sca-1, occupying a
perivascular niche and showing broad trans-germ layer
potency in vitro and in vivo [19].
Epicardial cells with the potential to transdifferentiate
into other cell lineages have been observed also in human
fetal and adult hearts [21, 22]. Limana and co-authors
showed that c-kit+ and CD34+ cells can be detected in
human fetal and adult epicardium as two distinct popula-
tions capable of giving rise to myocardial precursors and
vascular cells in vitro [21]. The authors further showed that,
in a mouse model of myocardial infarction, there was an
increase in c-kit+ cells in the subepicardial space. Interest-
ingly, 3 days after infarction these cells expressed GATA4,
whereas at 1 week c-kit+ cells co-expressed endothelial or
smooth muscle cell markers [21]. In another study, it has
been observed that in vitro culture of primary human epi-
cardial cells present characteristics of smooth muscle cells
(SMCs) if treated with transforming growth factor-beta or
bone morphogenetic protein 2 (BMP2) [22].
Although promising in their possible therapeutic applica-
tions, these studies require more experimental analyses to
determine the efficiency and efficacy of epicardial cells to
regenerate the heart after injury and to differentiate in dif-
ferent lineages in vitro.
So far, the most characterized adult progenitor cells in the
heart are the Lin−/c-kit+ cells. These cells are self-renewing,
clonogenic, multipotent in vitro and in vivo, and give rise to
myocytes, smooth muscle and endothelial vascular cells
(Fig. 1) [23].When injected into an ischaemic rat heart, a
population of these cells or their clonal progeny reconsti-
tutes large portions of the injured myocardial wall [23]. The
regenerated myocardium contains small myocytes that
present the anatomical, biochemical and functional properties
of young myocytes [23]. Recent evidence shows that
Lin−/c-kit+ cells also have the ability to form conductive and
intermediate-sized coronary arteries when injected in infarcted
rat heart [24]. Resistance arterioles and capillaries are
connected with primary coronary circulation, indicating that
Lin−/c-kit+ cells have a dual role in vessel and contractile
muscle formation [24].
Importantly, not all studies recognize c-kit-positive car-
diac progenitor cells as in vivo promise for therapeutic
cardiac regeneration. Indeed, using transgenic reporter mice
and through genetic read-outs for lineage tracing, c-kit cells
did not differentiate in cardiomyocytes in vivo after trans-
plantation, questioning their claimed efficiency in regener-
ating the rodent hearts [25]. Interestingly, Zaruba and co-
authors used double transgenic beta actin-green fluorescent/
alpha Myosin Heavy Chain-nuclear beta galactosidase mice
(ACT-EGFP/MHC-nLAC) to show that c-kit+ cardiac cells
from neonatal hearts acquired a cardiomyogenic phenotype
in coculture with fetal mouse cardiomyocytes, independent-
ly of cell fusion [26]. This activity was diminished in c-kit+
cells isolated from adult hearts [26]. Moreover, c-kit+ cells
from adult hearts failed to undergo cardiomyogenic differ-
entiation when transplanted into infarcted adult hearts, indi-
cating that the ability of cardiac specific c-kit+ cells to
acquire a cardiomyogenic phenotype is subject to temporal
limitations or that the cardiomyogenic population is lost
[26]. Interestingly, it has been identified a population of
c-kit+ cells in human atrial biopsies that could be subdivided
based on the expression of CD45 [27]. The c-kit+CD45− cells
coexpressed endothelial cell markers such as CD31, CD34
and FLK-1, whereas the c-kit+CD45+ population was deter-
mined to be of mast cell identity [27]. However intriguing,
further characterization of the above human populations
should be supported by ex vivo expansion and differentiation
studies, as well as cell transplantation analyses, to rule out
their efficiency in cardiac regeneration.
In addition to the above populations, cells growing into
spherical structures termed cardiospheres [28] are recog-
nized as a distinct adult progenitor cell population.
Cardiospheres are a heterogeneous population of cells
obtained from adult hearts (e.g. from an endomyocardial
biopsy) in culture (Fig. 1). These cells form a three-
dimensional spherical structure with high proliferative
rate and capable of forming differentiated contractile
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cardiomyocytes [28, 29]. Transplanted in murine [28] and rat
[30] models of myocardial infarct, cardiospheres improved
left ventricular function and decreased scar size.
Interestingly, it has been shown that allogeneic transplan-
tation of cardiospheres in a rat myocardial infarct model
without immunosuppression is safe, promotes cardiac re-
generation and improves heart function, mainly through
stimulation of endogenous repair mechanisms [30]. The
indirect mechanism of action suggests the persistence of
benefit after removal of the transplanted cells by the host
immune system and has motivated the testing of allogeneic
cardiospheres in humans (Fig. 1) [31].
Hoechst exclusion cells, contained in a Verapamil-
sensitive side population, have been isolated from adult
murine hearts, showing spontaneous beating areas if treated
with oxytocin or trichostatin A [32]. In vivo, they are
present in the perivascular area and upon injury differentiate
in cardiomyocytes, endothelial and smooth muscle cells in a
percentage of 4.4, 6.7 and 29 %, respectively [32]. Their
therapeutic potential has yet to be investigated making
this population not as fully exploited as others described
above.
Although resident cardiac progenitor cell populations
have now been identified, the insufficiency of endogenous
stem cells to alleviate acute and chronic damage to mam-
malian cardiac tissue remains to be overcome. Overall, the
paucity in progenitor cell number in aged or diseased hearts
makes difficult to expand them to replace the massive
amount of cardiomyocytes lost during ischemia.
Pluripotent Stem Cells
New research avenues involving exogenously administered
pluripotent stem cell-derived cardiomyocytes have shown
cardiac function improvement in animal models of myocar-
dial repair, underscoring their therapeutic potential. There-
fore, considerable emphasis has been placed on enhancing
differentiation of these cells and exploiting their therapeutic
use as a goal of regenerative medicine.
Pluripotent stem cells have the capacity to differentiate
into cells derived from any of the three germ layers (Fig. 1).
Embryonic stem cells (ESC) are pluripotent stem cells with
the greatest potential to differentiate into cardiomyocytes
and replace the damaged cardiac muscle. In vitro analysis
showed that human ESC-derived cardiomyocytes spontane-
ously contract and generate action potentials of multiple
cardiac phenotypes, as well as expression of specific cardiac
protein and myofibrillar organization [33]. In vivo ESC-
derived cardiomyocytes can function as pacemakers in mod-
els of atrioventricular-blocked hearts [34]. In an acute car-
diac injury model, human ESC-derived cardiomyocytes
formed gap junction and grafted cells behaved as a syncy-
tium. Most studies report functional improvement as appar-
ent as 4 weeks [35, 36], whereas one study extended the
analysis up to 12 weeks in mice, in which the benefit of the
injected cells was no longer present [37]. Although it cannot
be ruled out that paracrine effects are responsible for the
increased functional parameters, most likely differences in
beating frequency may account for the failure to improve
1. Bone marrow-derived 
stem cells
2. Pluripotent stem cells
from the inner cell mass 
of the blastocyst 
3. Adult differentiated cells 
(e.g. dermal fibroblast)
+ factors and/or 
chemicals
Retroviral infection with 





Isolation from adult heart biopsies
5. Sca-1 and c-Kit adult
CSCs
Ischaemic heart disease
Fig. 1 Stem cell therapies to
heal infarcted heart. Different
stem cells have been used to
recover cardiac function after
ischaemic diseases. Bone
marrow-derived stem cells (1),
c-kit adult cardiac stem cells (5,
CSCs) and cardiospheres (4)
have been employed in clinical
trials with promising results.
Immunogeneicity and ethical
problems obstruct the usage
of ESCs and iPSCs (2, 3)
for clinical studies. The limits
and potentialities of Wt1-
Sca-1-positive epicardial cells
have not been exploited
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long-term cardiac functions in mouse models (murine heart
beats 300–600 times per minute, while human cardiomyo-
cytes beat 60–100 times per minute) [38].
The use of non-autologous human ESC in a therapeutic
context is confounded by their inherent immunogenicity,
although mixed chimaerism and reversible reactivation of
thymic function by analogues of luteinizing-hormone-
releasing hormone showed immune tolerance after trans-
plantation of ESCs [39]. In practice, the advantages of using
ESCs are often outweighed by ethical and political consid-
erations, which constitute the chief impediments to the
clinical application of these cells. Several strategies to over-
come the use of human embryos involve the production of
pluripotent stem cells from adult cells. Remarkably, retroviral-
mediated overexpression of only four proteins (OCT4, SOX2,
Myc and KLF4) in mouse embryonic or adult fibroblasts
generated inducible pluripotent stem-cell-like cells (iPS) able
to differentiate into derivatives of the three germ layers
(Fig. 1) [40]. iPS cells are ideal candidates for autologous
transplantation, since production of patient specific iPS cells
can theoretically overcome the problem of rejection and im-
munosuppressive therapy.
However promising, both iPS and ESCs form teratomas
if undifferentiated derivatives are present in the pool of
injected cells. The carcinogenic nature of ESCs and iPS
limits their therapeutic application and poses an important
challenge. Furthermore, they form heterogeneous populations
of cardiomyocytes in culture (atrial, nodal and ventricular),
having different action potentials. Therefore, effective differ-
entiation methods need to be developed to yield highly puri-
fied cell populations for transplantation to avoid arrhythmias
and tumour formation.
Indeed, direct transdifferentiation of fibroblast in cardio-
myocytes has been acclaimed as a safer and more practical
step towards autologous cell therapy [41]. The combination
of three transcription factors (MEF2C, GATA4, TBX5) ac-
tivated the Myh6 promoter in murine cardiac fibroblasts.
About 4 % of the cells expressed cardiac troponin T and 1 %
showed spontaneous beating. Another attempt showed that
by blocking the JAK–STAT pathways and by the addition of
BMP4, 40 % of murine embryonic fibroblasts expressed
Troponin T [42], indicating an increased efficiency in pro-
ducing autologous cardiomyocytes.
Although encouraging results in tumour reduction have
been obtained using methods to preselect for ESCs that dif-
ferentiate along a cardiac lineage, or to preserve pluripotency
in absence of Myc for iPS cells, a mere reduction in tumour
incidence will not be sufficient to justify clinical trials.
Bone Marrow and Mesenchymal Stem Cells
Considerable interest in bone marrow-derived cells (BMCs)
was prompted by Orlic report describing a bone marrow
stem cell population lineage negative (Lin−) and c-kit+
capable of transdifferentiating into cardiomyocytes and in-
ducing regeneration of murine myocardial tissue after in-
farct [8]. In adult human hearts, the first evidence that adult
BMCs participate in the formation of cardiomyocytes was
based on reports of Y-chromosome-positive cardiomyocytes
in female donor hearts transplanted in male recipients [43].
However promising, further studies in animal models of
myocardial infarction showed that BMCs differentiated into
cardiomyocytes after transplantation but at a very low rate
[44]. In other analyses, it was shown that that BMCs do not
form cardiomyocytes but instead become mature blood cells
after transplantation [6, 45]. Furthermore, additional studies
have indicated that BMCs are capable of fusing with car-
diomyocytes, explaining the appearance of BMC-derived
myocytes [7, 46]. Although no consensus exists on whether
BMCs differentiate into cardiomyocytes in vivo, animal
studies and clinical trials (described in the next paragraph)
have shown improvements in ventricular function when
BMCs are administered after infarction, implicating para-
crine signalling as the major mechanism of action [47, 48].
Being BMCs composed of a heterogeneous cell population
(haematopoietic stem cells, endothelial stem cells, multipotent
adult progenitor cells, mesenchymal stem cells) [49], the
beneficial outcomes may derive from one or a combination
of several distinct subsets of cells. Among them, mesenchy-
mal stem cells (MSCs) have received increasing interest in
recent years for their immunoregulatory function and benefi-
cial effects in healing damaged tissues.
MSCs were first identified in bone marrow [50] and
recently have been found in adipose tissue [51]. These cells
are multipotent and can differentiate into bones, cartilage
and adipocytes [52].
In vitro approaches to determine their cardiac lineage com-
mitment showed that MSCs from bone marrow, exposed to 5-
azacytidine, differentiated into cardiomyocytes, exhibiting
spontaneous action potential and mature sarcomeres [53].
Furthermore, human MSCs expressed cardiac protein in vitro
by creating three-dimensional aggregates [54].
In clinical studies, MSC beneficial effects are well known.
Indeed, these cells are used to treat secondary progressive
multiple sclerosis (NCT01056471), chronic allograft ne-
phropathy (NCT00659620) and as prevention for graft
rejection and graft-versus-host disease (NCT00504803,
NCT00972660, NCT00366145, NCT00284986).
In cardiovascular studies, the administration of MSCs to
pig infarcts stimulated endogenous CPCs to contribute to
repair processes [55]. In clinical trials, intracoronary admin-
istration of large numbers of autologous MSCs in patients
with acute myocardial infarction (AMI) induced a 14 %
improvement in ejection fraction [56]. Furthermore, alloge-
neic MSCs administered to patients intravenously within
10 days of infarction were well tolerated and were associated
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with decreased arrhythmias and an improvement in some
indices of contractile function [57].
From the above studies, it is clear that the main function
of MSCs is to elicit immunosuppression in inflammatory
environments. Indeed, MSCs hold an immunoregulatory
capacity by inhibiting T and B cells, as well as natural killer
cells and dendritic cells [58]. Furthermore, MSCs are also
immunoprivileged cells, due to the low expression of class
II major histocompatibility complex [58], favouring therefore
their usage in allogeneic transplantation studies.
In future analysis, it would be interesting to investigate
whether a resident cardiac MSC population participate to
cardiac repair by regulating inflammatory response and
eliciting angiogenesis and remodelling after infarction.
New Understanding in Cell Therapy and Cardiac Function
Amelioration
Despite the lack of agreement in the beneficial outcomes of
resident stem cells in regenerating infarcted hearts, the major-
ity of studies in which BMCs were infused into infarcted
murine hearts showed an improvement of global cardiac func-
tion and enhancement of blood flow (Fig. 1). Based on these
results, human clinical trials were initiated in 2001 to treat
patients with cardiac ischemia with autologous circulating
blood or bone marrow-derived cells. The initial pilot studies
(TOPCARE-AMI, BOOST trials) showed an improvement of
global left ventricular ejection fraction by six to nine percent-
age points [59, 60]. These results were confirmed in a larger,
double-blind, randomized trial called REPAIR-AMI. In this
study, the global and regional ejection fraction in the bone
marrow-treated group improved modestly but significantly by
2.9 % compared to the placebo-treated group. Notably, a
larger study called ASTAMI trial did not show any benefit
on the left ventricular functional parameters [61]. The two
trials differed in the treatment of the isolated cells and this
could have affected their functional capacity.
In a systematic review, Clifford and co-authors observed that
BMCs treatment in acute myocardial infarct patients improved
left ventricular ejection fraction over conventional therapies
such as primary angioplasty in long-term follow-up analyses
(60 months) [62]. Increased ejection fraction correlated with
reduced infarct size and cardiac wall motion, although the
incidence of mortality and morbidity was not statistically sig-
nificant compared to conventional therapies [62].
Recently, two phase 1 trials showed promising results in
cell therapy by employing autologous transplantation of
cardiospheres [31] or c-kit-positive CSCs (Fig. 1) [63].
The study by Bolli and colleagues, Stem Cell Infusion in
Patients with Ischemic Cardiomyopathy (SCIPIO), tested
the safety and efficacy of c-kit+ CSCs for the treatment of
ischaemic heart disease. The initial results showed that
1 year after intracoronary infusion of these cells, infarct size
decreased by 30 % and ejection fraction increased 8 % after
only 4 months. The second study by Makkar and colleagues,
called Cardiosphere-Derived Autologous Stem Cells to Re-
verse Ventricular Dysfunction (CADUCEUS), showed that
6 months after intracoronary infusion of cardiospheres, re-
gional contractility and viable heart mass increased, while scar
mass decreased as assessed by magnetic resonance. These
data correlated with survival of all patients receiving the cells
and with lack of tumour formation, prompting the employ-
ment of the cells for further, large phase II clinical trials.
Promising as these studies may be, significant challenges
remain to be overcome. Whereas c-kit+ CSCs infusion recover
ejection fraction [63], cardiospheres transplantation improved
local systolic function without affecting ejection fraction [31].
To shed light on these contradictory results, two reports
showed that measurements of local function underlying
decrease or increase of wall stresses after myocardial infarc-
tion and cell transplantation are more indicative than meas-
urements of global function, such as ejection fraction and/or
fractional shortening. The report by Williams et al. [64]
shows that intramyocardial injection of autologous bone
marrow progenitor cells in patients with ischaemic cardio-
myopathy induces improved regional function and reverse
remodelling 3 months and 1 year after cell injection, respec-
tively, without significant increase in ejection fraction meas-
urements [64]. Indeed, reverse remodelling induced by cell
therapy cause declines in systolic and diastolic volumes so
that ejection fraction increase is obscured.
The report by Wall et al. [65] simulated theoretically the
effects of injection of small volume of any material into the
myocardial wall of infarcted hearts. The data indicate that a
small fractional change (0.5 to 5 %) in myocardium wall
volume can alter cardiac mechanics, decreasing wall stresses,
without improving global function as measured by stroke
volume/end diastolic pressure (SV/PED) [65]. These short-
term mechanical effects are dependent on the location of the
injection, the fractional volume of material added and its
relative stiffness to the local myocardium. Moreover, the
global pressure–volume relationships, the SV/VED, and the
often-reported cardiac metric ejection fraction can be affected
by adding non-contractile material [65].
Although needing more study, these results suggest that
specific benefits in cardiac function may be derived by
reducing elevated local wall stresses implicated in pathologi-
cal remodelling of the myocardium after infarct.
Importantly, cardiac pump function mediated by cardio-
myocyte replacement must be supported by revascularization
of the tissue for functional recovery. Although it is known that
angiogenesis and arteriogenesis are both mediated by prolif-
erating endothelial cells and their capacity to branch and
connect with each other, it has been observed that the cells
of the innate immune system take part in these processes in an
unexpected manner.
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The following section describes in detail the contribution
of monocyte and macrophage (MC/Mϕ) populations in
regenerative processes and how they have been recently
classified as progenitor cells.
Monocytes/Macrophages and Regeneration
Monocytes (MC) consist of a heterogeneous multifunctional
cellular population that plays important roles in immune de-
fence, inflammation and tissue remodelling [66]. They do so by
phagocytosis, antigen processing and presentation, and by cy-
tokine production. Under certain stimuli, circulatingmonocytes
give rise to a variety of tissue-resident macrophages (Mϕ)
throughout the body, as well as to specialized cells such as
dendritic cells and osteoclasts [67]. Monocytes are known to
originate in the bone marrow from a common myeloid progen-
itor that is shared with neutrophils, and they are then released
into the peripheral blood, where they circulate for several days
before entering tissues and replenishing the tissue macrophage
populations. The morphology of mature monocytes in the
peripheral circulation is heterogeneous, and these cells consti-
tute 5–10 % of peripheral blood leukocytes in humans [66].
Studies of the mononuclear phagocyte system, using mono-
clonal antibodies specific for various cell-surface receptors and
differentiation antigens, have shown that there is substantial
heterogeneity, which most probably reflects the specialization
of individual macrophage populations within their microenvir-
onments. The identification of heterogeneity among peripheral
blood monocytes—first, in humans [68], and more recently, in
mice [69]—has provided a powerful insight into the nature of
myeloid cell subsets and novel ways to assess cell fate and
function in vivo. Indeed, analysis of the different populations
showed that, in humans, monocytes are present in circulation as
CD14highCD16− andCD14lowCD16+ cells, enrolled in the tissue
during inflammation and chronic disease respectively [70]. In
mouse, it is known and well established that monocytes consists
of two distinct subsets: the inflammatory cells (Ly-6Chigh) and
the Ly-6Clow cells, patrolling the resting vasculature, and partic-
ipating in resolution of inflammation [69] (Fig. 2).
In addition to their pro- and anti-inflammatory response,
MC/Mϕ promote tissue repair and regeneration eliciting
angiogenesis and cell survival. Indeed, it has been found
that monocyte depletion by 5-fluorouracil totally abolishes
collateral growth in a model of acute femoral artery ligation













Fig. 2 Monocyte/macrophage populations in cardiac repair. Two dif-
ferent populations of monocytes are mobilized to the heart after infarct.
The inflammatory monocytes Ly-6Chigh ( ) are mainly stored in the
spleen, while the anti-inflammatory, pro-angiogenic monocytes Ly-
6Clow ( ) patrol vessels and participate to resolution of inflamma-
tion. Transdifferentiation from one type to the other has been reported,
although Ly-6Clow may occur to the heart from other organs.
Macrophage/monocyte populations ( ) have been shown to in-
teract with tip cells eliciting their fusion in developing brain. In
addition, they have been shown to drill tunnels into the myocardial
tissue to create conduits for the organization of fibro-vascular struc-
tures. The origin and phenotype of this specific population has not been
analysed. Smooth muscle cells and erythrocytes
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Mϕ are present in the tissue as M1 and/or M2 population. M1
Mϕ are associated with muscle necrosis, while M2 population
invades muscle once necrotic cells have been removed and is
associated with myofiber regenerative [72]. In injured skeletal
muscle, partial depletion of the Mϕ population impairs mus-
cle regeneration, whereas reconstitution of bone marrow
restores regeneration [70]. Furthermore, it was shown that
the function of Mϕ in regenerating skeletal muscle is to
support and promote cell growth and to establish cell–cell
interaction that protects myogenic precursor cells from apo-
ptosis [70]. Arnold and co-workers showed that injured skel-
etal muscle recruitsMCs exhibiting inflammatory profiles that
operate phagocytosis and rapidly convert to anti-inflammatory
Mϕ that stimulate myogenesis and fiber growth [70]. In an
attempt to provide genetic link between the heterogeneous
properties of MC/Mϕ population and their regenerative ca-
pacities, it has been shown that CREB-mediated induction of
Cebpb expression is required in infiltrating macrophages for
upregulation of M2-mediated anti-inflammatory cytokine re-
lease and muscle regeneration [73].
In addition to their efficiency in re-establishing skeletal
muscle morphology and function after injury, MC/Mϕ pop-
ulation has been shown to promote vessel formation after
ischaemic damage of the myocardium and in the developing
brain. Interestingly, a reduction in the number of vessels
containing smooth muscle cells (SMCs) has been observed
after macrophage depletion in injured myocardium, indicat-
ing that MC/Mϕ are not only regulators of formation of the
new blood vessels but also of the subsequent maturation of
the newly formed vessels [74]. Indeed, Danenberg showed
that macrophage depletion during neointima formation sig-
nificantly reduced proliferation of SMCs [75]. In different
studies, Moldovan and co-authors demonstrated that macro-
phages drill tunnels in the ischaemic myocardium by acti-
vating metalloelastases that digest the extracellular matrix
and create conduits for the organization of fibro-vascular
structures [76]. Fantin and co-authors, by combining the
analysis of mouse mutants defective in macrophage devel-
opment or VEGF signalling, showed that macrophages pro-
mote tip cell fusion, playing a hitherto unidentified and
unexpected role as vascular fusion cells [77].
Taken together, these studies show that MC/Mϕ functions
relate to their heterogeneous population and have a specific
genetic profile. Their properties cannot be summarized uniquely
as inflammatory and/or phagocytic but also cover angiogenesis,
arteriogenesis and tissue regeneration/remodelling (Fig. 2).
A Novel Role for Monocyte/Macrophage Populations as
Endothelial Progenitor Cells
The concept that monocytes are able to contribute to angio-
genesis is not novel. Urbich and colleagues showed that the
supposed EPCs have distinct monocytic features and can be
cultured from CD14-positive cells [78]. In other studies, De
Palma and colleagues showed that a subset of monocytic
cells expressing Tie2 and VEGFR2 (Flk1) play a pivotal
role in tumour angiogenesis [79, 80]. In a recent report, Kim
and co-workers observed that circulating monocytes
expressing F4/80, CD31 and VEGFR2 contribute to tumour
angiogenesis and revascularization following ischemia [81].
Interestingly, several studies showed that MC/Mϕ elicit
angiogenesis and possibly arteriogenesis [71, 82] by releas-
ing pro-angiogenic factors (e.g. agiopoietin, VEGF, bFGF),
but also transdifferentiating into various non-phagocytes,
such as mesodermal and neuroectodermal lineages [83].
Kuwana and co-authors described a primitive cell popula-
tion termed monocyte-derived multipotential cells (MOMC)
that can differentiate into several distinct mesenchymal cell
types, including bone, fat, skeletal and cardiac muscle [83].
MOMCs express several endothelial markers (VE-cadherin,
VEGFR1) and are able to uptake acetylated low-density
lipoproteins [83]. In a recent publication, it has been shown
that human MOMCs incorporated into new forming blood
vessels as endothelial cells, indicating that, in a permissive
environment, monocytic cells can differentiate into endothe-
lial cells and may represent an autologous source of cells for
therapeutic vasculogenesis [84].
The potential of haematopoietic cells to transdifferentiate in
endothelial-like cells can be justified by their common origins.
Indeed, the concept of crosstalk among the haematopoietic
and endothelial lineage is not entirely hypothetical. During
embryogenesis, both endothelial and haematopoietic cells
derive from a common ancestor, the hemangioblast. Specific
environmental factors such as a gradient of FGF expression
induce the hemangioblasts to preferentially differentiate to-
wards the endothelial or haematopoietic lineage. In mouse
embryo, neovascularization is influenced by monocytes and
by their mature derivatives macrophages [82, 85–87], present
in the angiogenic fields [88, 89] and preceding the advance-
ment of new capillaries [90]. The possibility that endothelial–
haematopoietic signalling occurs in a specific subset of mye-
loid cells may derive from an ancestral and communal lineage.
Although several lines of evidence support the fact that
MC/Mϕ contribute to postnatal vasculogenesis and have a
role in angiogenesis following ischaemic myocardial injury, it
is not certain if certain MC/Mϕ can become fully functional
endothelial cells or if their contribution in angiogenesis is
restricted to the production of vascular growth factors. Eluci-
dation of these putative functions is necessary to fully under-
stand the role of monocyte subsets in cardiac repair.
Monocyte/Macrophage Function in Heart Failure
The function of distinct MC/Mϕ populations in heart repair
has been recently investigated [91]. Nahrendorf et al.
showed that two distinct subsets of MC/Mϕ participate in
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myocardial healing after infarct in a sequential manner
through phase I (1–3 days) and phase II (4–7 days) [91].
CD11bhigh/Ly-6Chigh cells exhibiting phagocytic and pro-
inflammatory functions, accumulates during phase I and
CD11bhigh/Ly-6Clow having attenuated inflammatory re-
sponse and expressing VEGF, are present during phase II
[91]. Depletion of phase I, but not phase II, resulted in larger
areas of debris and necrotic tissue, indicating that removal of
debris requires phase I and its accompanying influx of pro-
teolytic and phagocytic Ly-6Chigh monocytes immediately
after coronary artery ligation. Conversely, the hearts of mice
that developed a native Ly-6Chigh response in phase I, but that
received the monocyte inhibitor clodronate liposome in phase
II, showed decreased deposition of collagen as well as reduced
numbers of microvascular-actin-positive smooth muscle cells
and CD31-positive endothelial cells. Thus, granulation tissue
formation and remodelling requires non-inflammatory, proan-
giogenic Ly-6Clow monocytes during phase II.
Interestingly, an extramedullary monocyte reservoir in
the spleen of mice has been discovered [92]. This monocyte
population residing in the spleen of mice is recruited to the
site of injury “en masse” as inflammatory and phagocytic
cells and represent 41 % of total monocytic population
infiltrating cardiac muscle after injury [92]. Thus, spleen
stores Ly-6Chigh monocytes readily recruitable to augment
inflammation at distant sites. Moreover, both subsets (Ly-
6Chigh and Ly-6Clow) exited the spleen in response to MI,
yet after 1 day, the ischaemic myocardium recruited Ly-
6Chigh monocytes selectively, suggesting that the excluded
Ly-6Clow monocytes may have dispersed to other tissues,
patrolled the vasculature, or accumulated in the infarct at a
later time (Fig. 2) [92].
Finally, Van Amerogen at al. have found that macro-
phage depletion markedly impaired wound healing, en-
hancing mortality after myocardial injury [74]. On the
same note, lack of MC/Mϕ is associated with earlier
development of myocardial dysfunction in hypertensive
rat [93]. It is well established that bone marrow mono-
nuclear cells (BM-MNC) increases significantly the per-
centage of ejection fraction of patients with acute
myocardial infarction after intra-coronary infusion (TOP-
CARE-AMI, BOOST trials) [60, 94]. Although none of
these studies determined the effective cell population
inducing cardiac function improvement, it is possible
to hypothesize that monocytes, being largely represented
among BM-MNCs, are the most active cells involved in
cardiac repair. One hypothesis is that the presence of
monocytes at the sites of vascular or myocardial injury
does not represent a catastrophic immune overreaction
but a futile attempt at tissue repair [67].
A clear molecular analysis of the cells mobilised at
different time points into the injured heart and their recruit-
ment signalling would be important to elucidate the cellu-
lar basis of current trials and to inform future therapeutic
approaches.
Concluding Remarks: From an Evolutionary Point
of View
Regeneration necessitates of a balanced interplay between
different cells and factors recruited to the injured organs
(Fig. 3). Resident and/or circulating stem cells and immune
cells may both participate in the reconstitution of lost
REGENERATION                                SCAR
• Inflammatory reactions
• Cell death
• Scar formation • Anti-inflammatory response
• Stem cell differentiation
• Revascularization
• Cardiomyocytes proliferation
• Inflammatory and anti-inflammatory reactions
• Cell death and proliferation
• Stem cell differentiation
• Monocytes/Macrophages for revascularization
THERAPEUTIC POTENTIALS
• Combinatorial stem cells/growth factors therapy
• Inflammatory/anti-inflammatory response regulation
No combinatorial approaches
Fig. 3 Balancing regenerative
processes. Cell therapy is not
sufficient to re-establish the
molecular and cellular equilib-
rium leading to function and
tissue integrity. Combinatorial
approaches must be developed
that take into account compo-
nents of the innate immune
system, regulating inflammato-
ry and anti-inflammatory re-
sponse, as well as new blood
vessel formation
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structures. Besides having important roles in orchestrating
tissue remodelling, the interplay occurring between the par-
ticipating cell populations in vertebrate regeneration is un-
known. As cardiac regeneration in higher vertebrates is
inefficient and scar tissue is formed at expense of cardiac
tissue, it appears that fast healing has been selected during
evolution of higher mammals at the cost of complete re-
placement of the lost tissue.
This apparent paradox may have profound implications
for the future of clinically relevant heart repair. As Richard
Goss wrote “Hence, before any intelligent attempt can be
made to restore regeneration where it does not normally take
place, it will be necessary to learn what physiological
advantages took precedence over regeneration in the course
of natural selection” [95]. Accordingly, the advantages of
epimorphic regeneration may be outweighed by refinements
in the adaptive immune system, overall those that enhanced
the acute inflammatory response in wounds [96]. Localized
injuries and infections that accompanied the predatory way
of life made possible by the development of hinged jaws,
evolved with the raise of the cellular components of the
adaptive system, allowing greater defences against patho-
gens in injured tissue, at the costs of tissue’s ability to
regenerate perfectly and restore function completely [97].
Indeed, components of the adaptive immune system have
been observed to interfere with regeneration [96]. Indeed,
regenerating tadpoles have weak cellular and humoral im-
munity, consisting only of IgM produced by B cells and
lacking memory cells [98]. The newt eye environment is
built to keep inflammation low during lens regeneration and
the peculiar restricted immune response for this organ is
associated to the presence of antigen specific regulatory T
cells (CD4+ and CD8+) that inhibit the induction and ex-
pression of pro-inflammatory cytokines [99].
Although protecting organ integrity and fast healing, scar
tissue in mammals can induce pathological outcomes in
organs such as the heart and the lung, and over active
immune system can cause autoimmune disorders, such as
rheumatoid arthritis and scleroderma. In the process of
human myocardial regeneration, re-activation of endoge-
nous stem cells or the use of exogenous sources of stem
cells for replacing loss of injured cardiomyocytes and endo-
thelial cells (Fig. 3) may not be sufficient to induce regen-
eration. It may therefore be important to reconsider the role
of monocytes and macrophages in the regenerative process-
es as a population of stem cells actively involved in postna-
tal vasculogenesis and in angiogenesis during tissue repair.
The identification of putative progenitor monocytes and
their manipulation in vitro may fuel the field of regenerative
medicine with novel approaches. In this context, mobiliza-
tion of monocyte/macrophage populations is considered a
desperate attempt for tissue repair more than a deteriorating
immune overreaction.
Therefore, important insights into the loss of regenerative
ability during the course of evolution are likely to come
from improved understanding of the cellular activities and
factors released during inflammation, clarifying the cells
and signals leading to regeneration.
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